U.S. flag An official website of the United States government
  1. Home
  2. Food
  3. Food Ingredients & Packaging
  4. Generally Recognized as Safe (GRAS)
  5. GRAS Notice Inventory
  6. Agency Response Letter GRAS Notice No. GRN 000643
  1. GRAS Notice Inventory

Agency Response Letter GRAS Notice No. GRN 000643

Recently Published GRAS Notices and FDA Letters

See also Generally Recognized as Safe (GRAS).

CFSAN/Office of Food Additive Safety

August 4, 2016

Susan Cho, Ph.D.
NutraSource, Inc.
6309 Morning Dew Court
Clarksville, MD 21029

Re: GRAS Notice No. GRN 000643

Dear Dr. Cho:

The Food and Drug Administration (FDA) is responding to the notice, dated March 23, 2016, that you submitted on behalf of ECA Healthcare, Inc. (ECA) in accordance with the agency’s proposed regulation, proposed 21 Code of Federal Regulations (CFR) 170.36 (62 FR 18938; April 17, 1997; Substances Generally Recognized as Safe (GRAS); the GRAS proposal). FDA received the notice on March 28, 2016, filed it on May 4, 2016, and designated it as GRAS Notice No. GRN 000643.

The subject of the notice is phosphatidylserine derived from fish lecithin (fish PS). The notice informs FDA of the view of ECA that fish PS is GRAS, through scientific procedures, for use as an ingredient in dairy product analogs (imitation milk and soy milk), grain products (nutritional bars: breakfast, granola, and protein), milk products (flavored milk and milk drinks, excluding fluid milk, milk-based meal replacements, and yogurt), and processed fruits and fruit juices (fruit flavored drink) at a level up to 100 milligrams (mg) phosphatidylserine per serving; in breakfast cereals and milk (fluid – regular, filled, buttermilk, and dry reconstituted) at a level up to 50 mg phosphatidylserine per serving; and, in medical foods at a level up to 300 mg phosphatidylserine per serving.

In an email dated July 1, 2016, you withdrew your notice in order to collect further information regarding comments FDA raised in an email sent to you on June 20, 2016. Given your email, we ceased to evaluate your GRAS notice, effective July 1, 2016, the date that we received your email.

In accordance with proposed 21 CFR 170.36(f), a copy of the text of this letter responding to GRN 000643, as well as a copy of the information in this notice that conforms to the information in the GRAS exemption claim (proposed 21 CFR 170.36(c)(1)), is available for public review and copying via the FDA home page at http://www.fda.gov/grasnoticeinventory.


Antonia Mattia, Ph.D.
Division of Biotechnology and GRAS Notice Review
Office of Food Additive Safety
Center for Food Safety and Applied Nutrition

Back to Top